One of the top leading startup companies that are making its way in the field of skin associated pathogens.
We all get conscious about our skin, especially for tanning and acne. To protect our skin, different experiments and trials have to be carried out. Vyome Therapeutics Inc. is one such pharmaceutical startup which is a clinical-stage speciality pharmaceutical company, which has ideal platform technologies and a strong pipeline of novel drugs for antibiotic-resistant acne and other opportunistic skin pathogens.
The members of the Vyome Therapeutics management team are leaders in this field. They have in-depth know-how, proven skills, and experience. They have introduced more than 50 products in dermatology and other life sciences sector.
They are in the constant search for innovation, discovery and development of new platform technologies and an important portfolio of innovative medicines for the treatment of antibiotic-resistant acne and other opportunistic skin diseases are becoming a society.
The company's flagship molecule (VB 1953), which addresses an unmet need in the market for prescription drug-resistant and current in phase II clinical trials. The acne drugs completed a clinical concept study at the end of 2017 with the expected results and initiated in the United States.
In early February 2017, Vyome announced the results of Phase 1 clinical trials after the US FDA accepted the new drug application from Vyome. Some of the investors in this project are Kalaari capitals, Romulus Capital, Iron Pillar, Aarin Capital, Navam Capital, IIFL Seeds Ventures Fund.
Vyome Biosciences was adjudged as "The Most Innovative Company of the Year 2016" in the MSME category. It was also a “2014 Red Herring Asia top 100 Winner in Life Sciences/Biotech Category”. Since then Vyome made to the news and in the competition with other pharma startups. They have received many awards for their amazing work.
The company has made tremendous progress and given the best results in terms of products. They provide pipelines and opportunities in creating platform strategy and associated publications pertaining to same.
Editor: Anomitra Dey